ZELTIQ Aesthetics, Inc. (NASDAQ:ZLTQ) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition.
|
announcing its financial results for the fourth quarter and full
year 2016. A copy of the press release is attached as Exhibit
99.1.
are being filed for the purposes of Section 18 of the Securities
Exchange Act of 1934.
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press Release issued on March 1, 2017, announcing
financial results for the fourth quarter and full year 2016. |
|
filing documents with the SEC, including preliminary and
definitive proxy statements relating to the proposed transaction.
The definitive proxy statement will be mailed to Company
stockholders in connection with the proposed transaction. BEFORE
MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS ARE
URGED TO READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS AND
ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH
THE PROPOSED MERGER OR INCORPORTED BY REFERENCE IN THE PROXY
STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors
and security holders may obtain free copies of these documents
(when they are available) and other related documents filed with
the SEC at the SECs web site at www.sec.gov, on the Companys
website at www.zeltiq.com or by contacting ZELTIQ Aesthetics
Investor Relations at (925) 474-2500.
officers may be deemed participants in the solicitation of
proxies from the stockholders of the Company in connection with
the proposed transaction. Information regarding the special
interests of the Companys directors and executive officers in the
proposed transaction will be included in the proxy statement
described above. These documents are available free of charge at
the SECs web site at www.sec.gov and from ZELTIQ Aesthetics
Investor Relations as described above. Information about Parents
directors and executive officers can be found in Allergans
definitive proxy statement filed with the SEC on March 25, 2016.
You can obtain a free copy of this document at the SECs website
at www.sec.gov or by accessing Parents website at
www.allergan.com and clicking on the Investors link and then
clicking on the SEC Filings link.
About ZELTIQ Aesthetics, Inc. (NASDAQ:ZLTQ)
ZELTIQ Aesthetics, Inc. is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians. It also offers consumables, which are CoolSculpting procedure packs that are needed to perform procedures using its CoolSculpting system. CoolSculpting is a non-invasive fat reduction procedure. CoolSculpting utilizes its controlled cooling technology to selectively reduce stubborn fat bulges. The CoolSculpting system includes CoolSculpting control unit and CoolSculpting applicators. Its consumable procedure pack includes consumable CoolGels, CoolLiners and Geltraps. In addition, each consumable procedure pack includes a disposable computer cartridge that it markets as the CoolCard. ZELTIQ Aesthetics, Inc. (NASDAQ:ZLTQ) Recent Trading Information
ZELTIQ Aesthetics, Inc. (NASDAQ:ZLTQ) closed its last trading session up +0.12 at 55.48 with 1,674,496 shares trading hands.
